Q3 Earnings Estimate for LMAT Issued By Barrington Research

LeMaitre Vascular, Inc. (NASDAQ:LMAT) – Equities researchers at Barrington Research lifted their Q3 2025 EPS estimates for LeMaitre Vascular in a research report issued on Wednesday, August 6th. Barrington Research analyst M. Petusky now expects that the medical instruments supplier will post earnings of $0.57 per share for the quarter, up from their prior forecast of $0.56. Barrington Research currently has a “Outperform” rating and a $95.00 price target on the stock. The consensus estimate for LeMaitre Vascular’s current full-year earnings is $1.94 per share. Barrington Research also issued estimates for LeMaitre Vascular’s Q4 2025 earnings at $0.60 EPS, FY2025 earnings at $2.25 EPS, Q2 2026 earnings at $0.69 EPS, Q3 2026 earnings at $0.63 EPS, Q4 2026 earnings at $0.65 EPS, FY2026 earnings at $2.58 EPS and FY2027 earnings at $2.94 EPS.

Separately, Cantor Fitzgerald boosted their price target on shares of LeMaitre Vascular from $92.00 to $95.00 and gave the stock a “neutral” rating in a research note on Wednesday. Four equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to data from MarketBeat.com, LeMaitre Vascular has a consensus rating of “Hold” and an average target price of $98.00.

LeMaitre Vascular Trading Down 2.1%

LMAT opened at $92.28 on Friday. The company has a debt-to-equity ratio of 0.46, a current ratio of 13.96 and a quick ratio of 13.83. The company has a market cap of $2.09 billion, a price-to-earnings ratio of 44.80, a price-to-earnings-growth ratio of 2.42 and a beta of 0.79. The firm has a 50 day simple moving average of $83.35 and a 200 day simple moving average of $86.65. LeMaitre Vascular has a fifty-two week low of $71.42 and a fifty-two week high of $109.58.

LeMaitre Vascular (NASDAQ:LMAT) last posted its quarterly earnings results on Tuesday, August 5th. The medical instruments supplier reported $0.60 earnings per share for the quarter, topping analysts’ consensus estimates of $0.57 by $0.03. The business had revenue of $63.15 million during the quarter, compared to the consensus estimate of $62.48 million. LeMaitre Vascular had a net margin of 20.08% and a return on equity of 13.67%. LeMaitre Vascular’s revenue for the quarter was up 15.0% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.52 earnings per share.

Institutional Investors Weigh In On LeMaitre Vascular

Large investors have recently bought and sold shares of the company. Principal Financial Group Inc. increased its stake in LeMaitre Vascular by 3.0% in the first quarter. Principal Financial Group Inc. now owns 111,865 shares of the medical instruments supplier’s stock valued at $9,385,000 after purchasing an additional 3,248 shares in the last quarter. Invesco Ltd. increased its position in shares of LeMaitre Vascular by 50.5% during the fourth quarter. Invesco Ltd. now owns 174,998 shares of the medical instruments supplier’s stock worth $16,124,000 after acquiring an additional 58,720 shares in the last quarter. Compass Planning Associates Inc increased its position in shares of LeMaitre Vascular by 91.4% during the first quarter. Compass Planning Associates Inc now owns 11,776 shares of the medical instruments supplier’s stock worth $988,000 after acquiring an additional 5,623 shares in the last quarter. Johnson Investment Counsel Inc. increased its position in shares of LeMaitre Vascular by 34.8% during the first quarter. Johnson Investment Counsel Inc. now owns 29,428 shares of the medical instruments supplier’s stock worth $2,469,000 after acquiring an additional 7,603 shares in the last quarter. Finally, Consolidated Planning Corp bought a new stake in shares of LeMaitre Vascular during the first quarter worth $947,000. Institutional investors own 84.64% of the company’s stock.

Insider Buying and Selling

In other LeMaitre Vascular news, CEO George W. Lemaitre sold 100,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 6th. The shares were sold at an average price of $93.51, for a total value of $9,351,000.00. Following the completion of the sale, the chief executive officer owned 1,727,003 shares of the company’s stock, valued at approximately $161,492,050.53. This represents a 5.47% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have sold a total of 200,000 shares of company stock valued at $17,907,857 over the last ninety days. 9.50% of the stock is currently owned by corporate insiders.

LeMaitre Vascular Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, September 4th. Shareholders of record on Thursday, August 21st will be paid a $0.20 dividend. This represents a $0.80 annualized dividend and a yield of 0.9%. The ex-dividend date of this dividend is Thursday, August 21st. LeMaitre Vascular’s dividend payout ratio is presently 38.83%.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.